RecruitingNCT05512169

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia

Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children (MPGx-INDALL)


Sponsor

University of Geneva, Switzerland

Enrollment

556 participants

Start Date

Dec 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). The project is an International multicenter setup. This collaborative research project between Switzerland and India includes one main center in Geneva that has conceptualized, designed, received grants for the study and two investigating centers in India (Puducherry and New-Delhi) involved in study design, patient care and recruitment for this specific study. All the participants for the study will be recruited form these two centers in India, and no patient recruitment is planned at main center i.e. Geneva. The study will be conducted in two phases. The first aims to investigate genetic predisposition (static germline variants) to early chemotherapy treatment related toxicities (TRTs). The second aims to investigate somatic genetic markers associated with the efficacy of steroid treatment among patients undergoing the standardized IciCLe-ALL-14 treatment protocol. A total of 500 children with ALL will be recruited to investigate primary objective of the study i.e. TRT, and a subset of 250 patients will be included to investigate another research question i.e. response to steroid therapy.


Eligibility

Min Age: 1 YearMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how variations in genes (pharmacogenomics) affect how children in India respond to treatment for acute lymphoblastic leukemia (ALL) — the most common childhood cancer. Understanding these genetic differences may help tailor treatment to reduce side effects and improve cure rates. **You may be eligible if...** - You are between 1 and 18 years old - You are of Indian origin - You have been newly diagnosed with ALL confirmed by lab testing - You have not previously received any cancer treatment - You are being treated according to a specific protocol (IciCle) - A parent or guardian can provide written consent **You may NOT be eligible if...** - You have already been treated for leukemia - You have Down syndrome - You have a specific subtype called mature B-cell ALL - You do not meet the treatment protocol's criteria Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

Dr. Sameer Bakhshi

New Delhi, India

Dr. Biswajit Dubashi

Puducherry, India

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05512169


Related Trials